As of June 18, Merck (MRK.US) pre-market trading rose more than 1%, to $128.88. Merck stated that the US Food and Drug Administration (FDA) has approved its next generation vaccine Capvaxive to protect adults aged 18 and over from pneumococcal disease. The company expects the vaccine to be available by the end of the summer, according to advice from CDC advisers. CDC advisers are expected to discuss the vaccine at a meeting later this month.
美股异动｜默沙东盘前涨超1% 肺炎球菌疫苗获美国FDA批准用于成年人
U.S. stock anomaly - Merck rose more than 1% in pre-market trading, and pneumococcal vaccine gets FDA approval for use in adults.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.